Ulcerative colitis relapse seen in half of patients after tofacitinib dose reduction: study
Half of patients with ulcerative colitis lose their remission response to tofacitinib after dose de-escalation, which is only “partially recaptured” with increasing maintenance dose, real-world data show.
Results from the largest cohort study to date also suggest that those with prior biologic failure and severe disease are at highest risk of losing response, according to Canadian doctors.
The University of Calgary-led team analysed data from 334 adults (median age 42) with ulcerative colitis treated with the Janus kinase (JAK) inhibitor from 2015-20 to assess its long-term efficacy and safety.
Most patients (94%) received 10mg oral tofacitinib twice daily as an induction dose and two-thirds de-escalated to a 5mg maintenance dose after an average period of eight weeks.
